PD-L1 expression

P1/2, N=314, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was closed early as the sponsor decided not to continue development of certain treatment combinations.

P3, N=669, Terminated, BeiGene | Active, not recruiting --> Terminated; This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.

NY-ESO-1 expression was associated with response to nivolumab, while PD-L1 expression, particularly CPS, may provide clinically relevant prognostic information. Integrated assessment of tumor-related biomarkers and the host immune microenvironment may further improve patient stratification in ESCC.

High-grade tumors exhibit features of immune engagement coupled with checkpoint-mediated regulation, supporting a model of adaptive immune resistance. These findings underscore the necessity of combination therapeutic strategies that simultaneously target ALK and immune checkpoint modulation in high-grade INMA.

ssRAB integrated with mobile CBCT-guided cryobiopsy had a high diagnostic yield for GGO-predominant PPNs with a favorable safety profile.

Moreover, low RAD18 expression predicted a favorable response to immune checkpoint blockade therapy, while its high expression correlated with anti-PD-1 resistance in triple-negative breast cancer. Collectively, our findings identify RAD18 as a potential pan-cancer prognostic biomarker and immunotherapeutic target, with targeting RAD18 holding promise for reversing immunotherapy resistance in solid tumors.

Collectively, these findings suggest that ASF1B deficiency exerts anti-tumor effects and anti-tumor immunity by regulating p53-related ferroptosis.

Both KRAS "OFF"" G12C inhibitors, sotorasib and adagrasib, are considered standard second-line therapy, albeit with a modest progression-free survival benefit over standard chemotherapy. Critical clinical questions remain open regarding the optimal patient population for combinations, the influence of co-occurring genomic alterations, intracranial activity of KRAS inhibitors and dose optimization. This review synthesizes current evidence on the biology, clinical efficacy, safety, and practical considerations for treating KRAS G12C-mutant NSCLC, providing clinicians with an up-to-date, evidence-based framework for therapeutic decision-making and highlighting areas requiring further investigation.

The immune microenvironment was found to influence the response to immunotherapy in EBVaGC. Detailed characterization of the immune microenvironment may enhance the selection of patients with EBVaGCs likely to respond to immunotherapy.

Despite these insights, its roles in myeloid-derived suppressor cells, neutrophils, and other stromal subsets remain poorly understood. Therefore, investigating PGRN's influence on these cells is crucial for understanding tumor progression and therapeutic resistance and may reveal novel strategies to disrupt PGRN-dependent inflammatory circuits and enhance anti-tumor immunity.

Gemcitabine pretreatment upregulated PD-L1 expression and enhanced CAR-T-mediated cytotoxicity. These findings demonstrate the feasibility of second-generation PD-L1 CAR-T cells, demonstrating preclinical efficacy and specificity, and validating a therapeutic strategy that targets the tumor microenvironment for these challenging cancers.

This case illustrates herpes zoster reactivation during Pembrolizumab-based chemo-immunotherapy in metastatic NSCLC. It emphasizes the importance of systematically excluding infectious causes in new cutaneous eruptions under immunotherapy and supports multidisciplinary management. These findings also highlight the need to further explore VZV screening and vaccination strategies in cancer patients undergoing immunosuppressive treatments.